You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 8,133,893


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,133,893
Title:Trazodone and trazodone hydrochloride in purified form
Abstract: A process of production of trazodone or trazodone hydrochloride that comprises the steps of: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40.degree. C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. ##STR00001##
Inventor(s): Marchetti; Marcello (Rome, IT), Iacoangeli; Tommaso (Rome, IT), Ciottoli; Giovanni Battista (Rome, IT), Biondi; Giuseppe (Castel Gandolfo, IT)
Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (Rome, IT)
Application Number:12/513,048
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,133,893
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process;

Drugs Protected by US Patent 8,133,893

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Angelini Pharma OLEPTRO trazodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022411-001 Feb 2, 2010 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Angelini Pharma OLEPTRO trazodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022411-002 Feb 2, 2010 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Pragma DESYREL trazodone hydrochloride TABLET;ORAL 018207-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Pragma DESYREL trazodone hydrochloride TABLET;ORAL 018207-002 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Pragma DESYREL trazodone hydrochloride TABLET;ORAL 018207-003 Mar 25, 1985 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Pragma DESYREL trazodone hydrochloride TABLET;ORAL 018207-004 Nov 7, 1988 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,133,893

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI2007A1603Aug 03, 2007
PCT Information
PCT FiledJuly 23, 2008PCT Application Number:PCT/EP2008/059640
PCT Publication Date:February 12, 2009PCT Publication Number: WO2009/019133

International Family Members for US Patent 8,133,893

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 067773 ⤷  Sign Up
Australia 2008285779 ⤷  Sign Up
Brazil PI0814448 ⤷  Sign Up
Canada 2693095 ⤷  Sign Up
China 101772490 ⤷  Sign Up
Cyprus 1115666 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.